A review of the S100 proteins in cancer

European Journal of Surgical Oncology

Volumn 34, Issue 4, 2008, Pages 357-364

  Salama, I ^a,b   Malone, P S ^c   Mihaimeed, F ^a   Jones, J L ^b  

^a NEWHAM UNIVERSITY HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Biomarker; Cancer; S100 protein

Indexed keywords

CALGRANULIN B; CHEMOATTRACTANT; MATRIX METALLOPROTEINASE; PROTEIN S 100; PROTEIN S100B; S100A11 PROTEIN; S100A2 PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CARCINOGENESIS; DATA BASE; DIAGNOSTIC ACCURACY; GENE EXPRESSION; HUMAN; KIDNEY CANCER; LUNG CANCER; MELANOMA; METASTASIS; MOUTH CANCER; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; STOMACH CANCER; THYROID CANCER; TUMOR GROWTH; UPREGULATION;

HUMANS; NEOPLASMS; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 40749143138     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.04.009     Document Type: Review

References (132)

1. Marenholz I., Heizmann C.W., and Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322 (2004) 1111-1122
2. Schafer B.W., Wicki R., Engelkamp D., Mattei M.G., and Heizmann C.W. Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics 25 (1995) 638-643
3. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Technol 60 (2003) 540-551
4. Moore B.W. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19 (1965) 739-744
5. Zimmer D.B., Cornwall E.H., Landar A., and Song W. The S100 protein family: history, function, and expression. Brain Res Bull 37 (1995) 417-429
6. Zimmer D.B., Wright Sadosky P., and Weber D.J. Molecular mechanisms of S100-target protein interactions. Microsc Res Technol 60 (2003) 552-559
7. Mueller A., Schafer B.W., Ferrari S., et al. The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem 280 (2005) 29186-29193
8. Grigorian M., Andresen S., Tulchinsky E., et al. Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem 276 (2001) 22699-22708
9. Santamaria-Kisiel L., Rintala-Dempsey A.C., and Shaw G.S. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 396 (2006) 201-214
10. Davies M.P., Rudland P.S., Robertson L., Parry E.W., Jolicoeur P., and Barraclough R. Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene 13 (1996) 1631-1637
11. Kriajevska M., Tarabykina S., Bronstein I., et al. Metastasis-associated Mts1 (S100A4) protein modulates protein kinase C phosphorylation of the heavy chain of nonmuscle myosin. J Biol Chem 273 (1998) 9852-9856
12. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33 (2001) 637-668
13. Hiratsuka S., Watanabe A., Aburatani H., and Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8 (2006) 1369-1375
14. Yen T., Harrison C.A., Devery J.M., et al. Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli. Blood 90 (1997) 4812-4821
15. Cornish C.J., Devery J.M., Poronnik P., Lackmann M., Cook D.I., and Geczy C.L. S100 protein CP-10 stimulates myeloid cell chemotaxis without activation. J Cell Physiol 166 (1996) 427-437
16. Devery J.M., King N.J., and Geczy C.L. Acute inflammatory activity of the S100 protein CP-10: activation of neutrophils in vivo and in vitro. J Immunol 152 (1994) 1888-1897
17. Lau W., Devery J.M., and Geczy C.L. A chemotactic S100 peptide enhances scavenger receptor and Mac-1 expression and cholesteryl ester accumulation in murine peritoneal macrophages in vivo. J Clin Invest 95 (1995) 1957-1965
18. Bonfrer J.M., Korse C.M., Nieweg O.E., and Rankin E.M. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77 (1998) 2210-2214
19. Andres R., Mayordomo J.I., Zaballos P., et al. Prognostic value of serum S-100B in malignant melanoma. Tumori 90 (2004) 607-610
20. Heizmann C.W. S100B protein in clinical diagnostics: assay specificity. Clin Chem 50 (2004) 249-251
21. Zissimopoulos A., Karpouzis A., Karaitianos I., Baziotis N., Tselios I., and Koutis C. Serum levels of S-100b protein after four years follow-up of patients with melanoma. Hell J Nucl Med 9 (2006) 204-207
22. Schlagenhauff B., Schittek B., Ellwanger U., Stroebel W., Blum A., Schwarz M., et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?. Melanoma Res 10 (2000) 451-459
23. Harpio R., and Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37 (2004) 512-518
24. Hauschild A., Engel G., Brenner W., et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 140 (1999) 1065-1071
25. Hauschild A., Michaelsen J., Brenner W., et al. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9 (1999) 155-161
26. Schultz E.S., Diepgen T.L., and Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 138 (1998) 426-430
27. Hamberg A.P., Korse C.M., Bonfrer J.M., and de Gast G.C. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 13 (2003) 45-49
28. Smit L.H., Korse C.M., Hart A.A., et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 41 (2005) 386-392
29. Guo H.B., Stoffel-Wagner B., Bierwirth T., Mezger J., and Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 31A (1995) 1898-1902
30. Davies B.R., O'Donnell M., Durkan G.C., et al. Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J Pathol 196 (2002) 292-299
31. Wang G., Rudland P.S., White M.R., and Barraclough R. Interaction in vivo and in vitro of the metastasis-inducing S100 protein, S100A4 (p9Ka) with S100A1. J Biol Chem 275 (2000) 11141-11146
32. Nikitenko L.L., Lloyd B.H., Rudland P.S., Fear S., and Barraclough R. Localisation by in situ hybridisation of S100A4 (p9Ka) mRNA in primary human breast tumour specimens. Int J Cancer 86 (2000) 219-228
33. Barraclough R. Calcium-binding protein S100A4 in health and disease. Biochim Biophys Acta 1448 (1998) 190-199
34. Takenaga K., Nakanishi H., Wada K., et al. Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas. Clin Cancer Res 3 (1997) 2309-2316
35. Zou M., Al-Baradie R.S., Al-Hindi H., Farid N.R., and Shi Y. S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer 93 (2005) 1277-1284
36. Zou M., Famulski K.S., Parhar R.S., et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab 89 (2004) 6146-6154
37. Belot N., Pochet R., Heizmann C.W., Kiss R., and Decaestecker C. Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the organization of their actin cytoskeleton. Biochim Biophys Acta 1600 (2002) 74-83
38. Cho Y.G., Nam S.W., Kim T.Y., et al. Overexpression of S100A4 is closely related to the aggressiveness of gastric cancer. Apmis 111 (2003) 539-545
39. Kimura K., Endo Y., Yonemura Y., et al. Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 16 (2000) 1125-1131
40. Gupta S., Hussain T., MacLennan G.T., Fu P., Patel J., and Mukhtar H. Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J Clin Oncol 21 (2003) 106-112
41. Saleem M., Kweon M.H., Johnson J.J., et al. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci U S A 103 (2006) 14825-14830
42. Andersen K., Nesland J.M., Holm R., Florenes V.A., Fodstad O., and Maelandsmo G.M. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 17 (2004) 990-997
43. Ambartsumian N.S., Grigorian M.S., Larsen I.F., et al. Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene 13 (1996) 1621-1630
44. Grigorian M., and Lukanidin E. Activator of metastasis in cancer cells, Mst1/S100A4 protein binds to tumor suppressor protein p53. Genetika 39 (2003) 900-908
45. Lee W.Y., Su W.C., Lin P.W., Guo H.R., Chang T.W., and Chen H.H. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Oncology 66 (2004) 429-438
46. Gongoll S., Peters G., Mengel M., et al. Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 123 (2002) 1478-1484
47. Hemandas A.K., Salto-Tellez M., Maricar S.H., Leong A.F., and Leow C.K. Metastasis-associated protein S100A4 - a potential prognostic marker for colorectal cancer. J Surg Oncol 93 (2006) 498-503
48. Flatmark K., Pedersen K.B., Nesland J.M., et al. Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol 200 (2003) 589-595
49. Yonemura Y., Endou Y., Kimura K., et al. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 6 (2000) 4234-4242
50. Barraclough R., Chen H.J., Davies B.R., et al. Use of DNA transfer in the induction of metastasis in experimental mammary systems. Biochem Soc Symp 63 (1998) 273-294
51. Davies B.R., Davies M.P., Gibbs F.E., Barraclough R., and Rudland P.S. Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the Oncogene EJ-ras-1. Oncogene 8 (1993) 999-1008
52. Davies B.R., Barraclough R., Davies M.P., and Rudland P.S. Production of the metastatic phenotype by DNA transfection in a rat mammary model. Cell Biol Int 17 (1993) 871-879
53. Levett D., Flecknell P.A., Rudland P.S., et al. Transfection of S100A4 produces metastatic variants of an orthotopic model of bladder cancer. Am J Pathol 160 (2002) 693-700
54. Lloyd B.H., Platt-Higgins A., Rudland P.S., and Barraclough R. Human S100A4 (p9Ka) induces the metastatic phenotype upon benign tumour cells. Oncogene 17 (1998) 465-473
55. Mathisen B., Lindstad R.I., Hansen J., et al. S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis 20 (2003) 701-711
56. Bjornland K., Winberg J.O., Odegaard O.T., et al. S100A4 involvement in metastasis. deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res 59 (1999) 4702-4708
57. Kriajevska M.V., Cardenas M.N., Grigorian M.S., Ambartsumian N.S., Georgiev G.P., and Lukanidin E.M. Non-muscle myosin heavy chain as a possible target for protein encoded by metastasis-related mts-1 gene. J Biol Chem 269 (1994) 19679-19682
58. Li Z.H., and Bresnick A.R. The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA. Cancer Res 66 (2006) 5173-5180
59. Dulyaninova N.G., Malashkevich V.N., Almo S.C., and Bresnick A.R. Regulation of myosin-IIA assembly and Mts1 binding by heavy chain phosphorylation. Biochemistry 44 (2005) 6867-6876
60. Li Z.H., Spektor A., Varlamova O., and Bresnick A.R. Mts1 regulates the assembly of nonmuscle myosin-IIA. Biochemistry 42 (2003) 14258-14266
61. Mandinova A., Atar D., Schafer B.W., Spiess M., Aebi U., and Heizmann C.W. Distinct subcellular localization of calcium binding S100 proteins in human smooth muscle cells and their relocation in response to rises in intracellular calcium. J Cell Sci 111 Pt 14 (1998) 2043-2054
62. Takenaga K., Nakamura Y., Sakiyama S., Hasegawa Y., Sato K., and Endo H. Binding of pEL98 protein, an S100-related calcium-binding protein, to nonmuscle tropomyosin. J Cell Biol 124 (1994) 757-768
63. Takenaga K., and Masuda A. Restoration of microfilament bundle organization in v-raf-transformed NRK cells after transduction with tropomyosin 2 cDNA. Cancer Lett 87 (1994) 47-53
64. Maelandsmo G.M., Florenes V.A., Mellingsaeter T., Hovig E., Kerbel R.S., and Fodstad O. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer 74 (1997) 464-469
65. Feng G., Xu X., Youssef E.M., and Lotan R. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Res 61 (2001) 7999-8004
66. Suzuki F., Oridate N., Homma A., et al. S100A2 expression as a predictive marker for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral cavity. Oncol Rep 14 (2005) 1493-1498
67. Liu D., Rudland P.S., Sibson D.R., Platt-Higgins A., and Barraclough R. Expression of calcium-binding protein S100A2 in breast lesions. Br J Cancer 83 (2000) 1473-1479
68. Lee S.W., Tomasetto C., Swisshelm K., Keyomarsi K., and Sager R. Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment. Proc Natl Acad Sci U S A 89 (1992) 2504-2508
69. Kyriazanos I.D., Tachibana M., Dhar D.K., et al. Expression and prognostic significance of S100A2 protein in squamous cell carcinoma of the esophagus. Oncol Rep 9 (2002) 503-510
70. Tsai S.T., Jin Y.T., Tsai W.C., et al. S100A2, a potential marker for early recurrence in early-stage oral cancer. Oral Oncol 41 (2005) 349-357
71. Smith S.L., Gugger M., Hoban P., et al. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. Br J Cancer 91 (2004) 1515-1524
72. Zech V.F., Dlaska M., Tzankov A., and Hilbe W. Prognostic and diagnostic relevance of hnRNP A2/B1, hnRNP B1 and S100 A2 in non-small cell lung cancer. Cancer Detect Prev 30 (2006) 395-402
73. Imazawa M., Hibi K., Fujitake S., et al. S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma. AntiCancer Res 25 (2005) 1247-1250
74. Ito Y., Yoshida H., Tomoda C., et al. Expression of S100A2 and S100A6 in thyroid carcinomas. Histopathology 46 (2005) 569-575
75. Tsai W.C., Tsai S.T., Jin Y.T., and Wu L.W. Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma. Mol Cancer Res 4 (2006) 539-547
76. Madsen P., Rasmussen H.H., Leffers H., Honore B., and Celis J.E. Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. J Invest Dermatol 99 (1992) 299-305
77. Madsen P., Rasmussen H.H., Leffers H., et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin. J Invest Dermatol 97 (1991) 701-712
78. Moog-Lutz C., Bouillet P., Regnier C.H., et al. Comparative expression of the psoriasin (S100A7) and S100C genes in breast carcinoma and co-localization to human chromosome 1q21-q22. Int J Cancer 63 (1995) 297-303
79. Celis J.E., Rasmussen H.H., Vorum H., et al. Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J Urol 155 (1996) 2105-2112
80. Moubayed N., Weichenthal M., Harder J., Wandel E., Sticherling M., and Glaser R. Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours. J Cancer Res Clin Oncol 133 (2007) 253-261
81. Emberley E.D., Niu Y., Leygue E., et al. Psoriasin interacts with Jab1 and influences breast cancer progression. Cancer Res 63 (2003) 1954-1961
82. Emberley E.D., Niu Y., Njue C., Kliewer E.V., Murphy L.C., and Watson P.H. Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer. Clin Cancer Res 9 (2003) 2627-2631
83. Emberley E.D., Murphy L.C., and Watson P.H. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 82 (2004) 508-515
84. Leygue E., Snell L., Hiller T., et al. Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma. Cancer Res 56 (1996) 4606-4609
85. Al-Haddad S., Zhang Z., Leygue E., et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 155 (1999) 2057-2066
86. Emberley E.D., Alowami S., Snell L., Murphy L.C., and Watson P.H. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast. Breast Cancer Res 6 (2004) R308-R315
87. Salama I., Meehaimeed F., Marshall J., et al. S100A7 and the basal phenotype. Eur J Surg Oncol 32 (2006) 262
88. Krop I., Marz A., Carlsson H., et al. A putative role for psoriasin in breast tumor progression. Cancer Res 65 (2005) 11326-11334
89. Kennedy R.D., Gorski J.J., Quinn J.E., et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res 65 (2005) 10265-10272
90. Vogl T., Leukert N., Barczyk K., Strupat K., and Roth J. Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. Biochim Biophys Acta 1763 (2006) 1298-1308
91. Yong H.Y., and Moon A. Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch Pharm Res 30 (2007) 75-81
92. Hermani A., De Servi B., Medunjanin S., Tessier P.A., and Mayer D. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 312 (2006) 184-197
93. Stulik J., Koupilova K., Osterreicher J., et al. Protein abundance alterations in matched sets of macroscopically normal colon mucosa and colorectal carcinoma. Electrophoresis 20 (1999) 3638-3646
94. Stulik J., Osterreicher J., Koupilova K., et al. The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass. Electrophoresis 20 (1999) 1047-1054
95. Cross S.S., Hamdy F.C., Deloulme J.C., and Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 46 (2005) 256-269
96. Mulligan K.T., Walker R.A., Hart I.R., and Jones J.L. The role of S100A9 in mediating the breast myoepithelial tumour-suppressor effect. J Pathol 207 (2005) 27A
97. Rafii S., and Lyden D. S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol 8 (2006) 1321-1323
98. Memon A.A., Sorensen B.S., Meldgaard P., Fokdal L., Thykjaer T., and Nexo E. Down-regulation of S100C is associated with bladder cancer progression and poor survival. Clin Cancer Res 11 (2005) 606-611
99. Kondo A., Sakaguchi M., Makino E., Namba M., Okada S., and Huh N.H. Localization of S100C immunoreactivity in various human tissues. Acta Med Okayama 56 (2002) 31-34
100. Rehman I., Azzouzi A.R., Cross S.S., et al. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. Hum Pathol 35 (2004) 1385-1391
101. Ito Y., Yoshida H., Tomoda C., et al. S100A4 expression is an early event of papillary carcinoma of the thyroid. Oncology 67 (2004) 397-402
102. Shi Y., Zou M., Collison K., et al. Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab 91 (2006) 2373-2379
103. Ito Y., Arai K., Nozawa R., et al. S100A9 expression is significantly linked to dedifferentiation of thyroid carcinoma. Pathol Res Pract 201 (2005) 551-556
104. Puskas L.G., Juhasz F., Zarva A., Hackler Jr. L., and Farid N.R. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. Cell Mol Biol (Noisy-le-grand) 51 (2005) 177-186
105. Li G., Gentil-Perret A., Lambert C., Genin C., and Tostain J. S100A1 and KIT gene expressions in common subtypes of renal tumours. Eur J Surg Oncol 31 (2005) 299-303
106. Lin F., Yang W., Betten M., Teh B.T., and Yang X.J. Expression of S-100 protein in renal cell neoplasms. Hum Pathol 37 (2006) 462-470
107. Carlsson H., Petersson S., and Enerback C. Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development. Int J Oncol 27 (2005) 1473-1481
108. Jiang W.G., Watkins G., Douglas-Jones A., and Mansel R.E. Psoriasin is aberrantly expressed in human breast cancer and is related to clinical outcomes. Int J Oncol 25 (2004) 81-85
109. Alowami S., Qing G., Emberley E., Snell L., and Watson P.H. Psoriasin (S100A7) expression is altered during skin tumorigenesis. BMC Dermatol 3 (2003) 1
110. Emberley E.D., Gietz R.D., Campbell J.D., HayGlass K.T., Murphy L.C., and Watson P.H. RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer. BMC Cancer 2 (2002) 28
111. Enerback C., Porter D.A., Seth P., et al. Psoriasin expression in mammary epithelial cells in vitro and in vivo. Cancer Res 62 (2002) 43-47
112. Emberley E.D., Murphy L.C., and Watson P.H. S100A7 and the progression of breast cancer. Breast Cancer Res 6 (2004) 153-159
113. Celis J.E., Gromova I., Gromov P., et al. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett 580 (2006) 2935-2944
114. Arai K., Teratani T., Kuruto-Niwa R., Yamada T., and Nozawa R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer 40 (2004) 1179-1187
115. Arnes J.B., Brunet J.S., Stefansson I., et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11 (2005) 4003-4011
116. Stulik J., Osterreicher J., Koupilova K., et al. Differential expression of the Ca2+ binding S100A6 protein in normal, preneoplastic and neoplastic colon mucosa. Eur J Cancer 36 (2000) 1050-1059
117. Komatsu K., Andoh A., Ishiguro S., et al. Increased expression of S100A6 (Calcyclin), a calcium-binding protein of the S100 family, in human colorectal adenocarcinomas. Clin Cancer Res 6 (2000) 172-177
118. Melle C., Ernst G., Schimmel B., et al. Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma. Int J Oncol 28 (2006) 195-200
119. Tanaka M., Adzuma K., Iwami M., Yoshimoto K., Monden Y., and Itakura M. Human calgizzarin; one colorectal cancer-related gene selected by a large scale random cDNA sequencing and northern blot analysis. Cancer Lett 89 (1995) 195-200
120. Cho Y.G., Kim C.J., Nam S.W., et al. Overexpression of S100A4 is closely associated with progression of colorectal cancer. World J Gastroenterol 11 (2005) 4852-4856
121. Komatsu K., Murata K., Kameyama M., et al. Expression of S100A6 and S100A4 in matched samples of human colorectal mucosa, primary colorectal adenocarcinomas and liver metastases. Oncology 63 (2002) 192-200
122. Komatsu K., Kobune-Fujiwara Y., Andoh A., et al. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer 83 (2000) 769-774
123. Tolson J.P., Flad T., Gnau V., et al. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 6 (2006) 697-708
124. Agerbaek M., Alsner J., Marcussen N., Lundbeck F., and Von der Maase H. Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients. Eur Urol 50 (2006) 777-785
125. Davies B.R. Gene products involved in metastasis of bladder cancer. Histol Histopathol 18 (2003) 969-980
126. Rehman I., Cross S.S., Catto J.W., et al. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. Prostate 65 (2005) 322-330
127. Heighway J., Knapp T., Boyce L., et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 21 (2002) 7749-7763
128. Matsubara D., Niki T., Ishikawa S., et al. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci 96 (2005) 844-857
129. Wang H., Zhang Z., Li R., et al. Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer. Int J Cancer 116 (2005) 285-290
130. Shimada A., Kano J., Ishiyama T., et al. Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development. Cancer Sci 96 (2005) 668-675
131. Mori M., Shimada H., Gunji Y., et al. S100A11 gene identified by in-house cDNA microarray as an accurate predictor of lymph node metastases of gastric cancer. Oncol Rep 11 (2004) 1287-1293
132. Lee O.J., Hong S.M., Razvi M.H., et al. Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas. Neoplasia 8 (2006) 843-850